Health ❯ Healthcare ❯ Pharmaceuticals

Cancer Treatment

Immunotherapy Breast Cancer Bladder Cancer Multiple Myeloma Clinical Trials Prostate Cancer Lung Cancer Non-Small Cell Lung Cancer Drug Development Small Cell Lung Cancer Cutaneous Squamous Cell Carcinoma Follicular Lymphoma Mantle Cell Lymphoma Targeted Therapy Keytruda Oncology Colorectal Cancer CAR T Cell Therapy Existing Drugs Ogsiveo 3SBio Licensing Deal Drug Pricing Tyrosine Kinase Inhibitors Chemotherapy Pembrolizumab Triple-Negative Breast Cancer Trastuzumab Deruxtecan PARP Inhibitors Monoclonal Antibodies Libtayo Opdivo Radioligand Therapy HER2-positive Breast Cancer PD-1 Inhibitors EGFR-mutated Non-small Cell Lung Cancer Opioid Treatment Head and Neck Cancer Endometrial Cancer Skin Cancer Ovarian Cancer Biosimilars CAR T-cell Therapy ALK-positive NSCLC Amtagvi Acute Myeloid Leukemia Oncology Research Basal Cell Carcinoma Menin Inhibitors Gastrointestinal Cancer mRNA Technology mRNA Therapies mRNA Therapy Radiation Therapy Springworks Therapeutics Gene Therapy Cost Reduction Life-saving Drugs Lymphoma Medication Supply

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

The purchase secures full control of anito-cel, a BCMA-directed cell therapy under FDA review with a December 23 action date.

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

AnaptysBio Seeks to Toss Tesaro Anticipatory‑Breach Claim in Jemperli Royalty Dispute

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

FDA Accepts Sonrotoclax NDA, Grants Priority Review for Relapsed Mantle Cell Lymphoma

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

Merck Beats in Q3 on Keytruda, Narrows 2025 Outlook as Gardasil Slumps in China

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma